Transition to Subcutaneous Immune Globulin 16.5% Improves Patient-Reported Quality of Life
SUGAR LAND, TX – (July 1, 2022) Subcutaneous immune globulin (IGSC) is indicated for the treatment of primary immunodeficiences (PID) and offers the convenience of self-administration, fewer systemic reactions, and more stable IgG levels compared to intravenous IG...
A 3-Year Evaluation of Antibiotic Resistance Patterns in Gram-Negative Genitourinary Tract Infections Treated in Outpatient Infusion Centers (POICs)
Published December 4, 2021 Richard L. Hengel, MD Brian S. Metzger, MD, MPH H. Barry Baker, MD, FACP John S. Adams, MD Ramesh V. Nathan, MD, FIDSA Rishi Bhattacharyya, MD Richard M. Mandel, MD, FIDSA Kimberly A. Couch, PharmD, MA, FIDSA, FASHP Claudia P. Schroeder,...
Healix Demonstrates Hospital Avoidance with Provision of Outpatient Antimicrobial Therapy (OPAT): A Leader in the Field for Over 30 Years
SUGAR LAND, TX – (July 9, 2020) Healix Infusion Therapy, LLC has demonstrated success in achieving hospital avoidance when providing outpatient antimicrobial therapy (OPAT) to patients with serious infections through physician offices. Healix manages over 70...
Recent Comments